AI Healthcare Also "Raising Shrimp": Health160 Surges Over 80% in Four Days, What Is the Market Really Betting On?

Capital markets often have a keener sense than industry transformations, but they are also more prone to collective over-enthusiasm and misjudgment.

When a company once labeled as a “registration referral” platform is suddenly redefined as “AI hospital infrastructure,” its sharp stock price swings are no longer just emotional outbursts but represent a violent shift in valuation models.

Health 160 (02656.HK) saw its stock price surge over threefold in less than seven months. Even with the upcoming first-time unlock pressure next week, it continued to rally on March 12, rising 13% and hitting a new high.

Behind this sustained surge, the real story worth revisiting isn’t just the rise itself but what the market is betting on.

Two Extreme Emotional Swings

The stock price movement of Health 160 epitomizes the emotional fluctuations of the Hong Kong tech sector in 2026.

Just a month ago, on February 11, the stock plummeted about 30% in a single day. At that time, the market’s logic was clear and cold: as a typical internet healthcare platform, Health 160, despite talking about AI medical narratives, still had slow-growing revenue and no profit.

Data showed that its pharmaceutical sales gross margin had long hovered around 1.4%. This low-margin model—selling drugs for tiny profit margins—was seen by capital markets as an inefficient traffic monetization with little room for imagination.

Eventually, the anticipation of unlocking shares, combined with doubts about the profitability of the sector, triggered a typical “emotional stampede.”

However, within just a few days, the narrative dramatically reversed. With the 2026 government work report for the first time proposing to “create a new form of intelligent economy,” and the explosive popularity of open-source AI agent OpenClaw in tech circles, Health 160 quickly shifted its focus to promoting AI agents like OpenClaw in hospital scenarios.

This move seemed to flip a valuation switch, causing the stock to rocket—rising over 80% in just four trading days. Since its listing in September 2025, its stock price has more than tripled.

Whether it’s short-term volatility or long-term technical strength, these are clearly not due to a fundamental change in the company’s core business overnight but rather a forced rewriting of its valuation model. The market no longer sees it as a low-frequency registration referral tool but begins to price it as “AI infrastructure.”

The surge in Health 160’s stock price is essentially a violent correction of the old valuation system, driven by policy dividends and technological hot spots acting as dual catalysts.

A Twenty-Year “Clumsy Effort” Revaluation: Fake “Medical OS” or True Moat?

From a market perspective, platform competition in internet healthcare has long entered the era of giants.

In the platform-based internet healthcare sector, players include Alibaba Health, JD Health; for doctor consultation platforms, there are Ping An Good Doctor; and for medical referral platforms, WeDoctor. Against these giants, Health 160 seems less advantageous.

But its latest operational data reveal some hard-to-copy “clumsy efforts.” By the end of 2025, Health 160 had established operational partnerships with 82 public secondary and above hospitals under the “160 AI Hospital” initiative, adding 52 new hospitals in Q4 alone—an increase of 420% quarter-over-quarter.

This explosive growth directly uncovers its core competitive advantage. In healthcare, technology can be purchased, but the ability to access and operate within hospitals’ core systems—its “pipeline”—is a scarce resource.

Hospitals’ strict requirements for data security, compliance, and stability create high industry barriers, making rapid entry difficult for most companies.

Health 160’s two-decade effort to build an ecosystem connecting over 44,000 medical institutions and 900,000 healthcare professionals has become the best soil for AI implementation.

When AI technology begins to penetrate healthcare systems, large models are relatively easy to acquire, but few companies can truly land and operate effectively. By deploying OpenClaw and continuously improving related applications, Health 160 is essentially embedding AI capabilities into hospital operations.

In this process, its existing SaaS systems and hospital relationships become indispensable carriers.

For Health 160, it is rapidly transforming into a potential “China Hospital OS.” Its logic is to convert low-frequency registration connections into high-frequency hospital operation services and data sharing. If this model succeeds, its business could evolve from a simple drug distributor to an industry infrastructure operator.

However, this does not necessarily mean it has achieved OS-level control; it may still be just a supplementary plugin for HIS vendors, and this needs time to verify. After all, there is a huge execution gap between “connection” and “operation.”

The Valuation Revolution in AI Medical Care: Why Is Capital Suddenly Repricing?

The “AI hospital” story is highly attractive, but Health 160 is at a delicate crossroads where unlocking shares and profit turning points intertwine.

Next week, the company will face its first share unlock. Trading at a historical high, this is a critical moment to test market confidence. Notably, recently, Health 160 was officially included in the Hong Kong Stock Connect, enhancing liquidity.

Meanwhile, optimistic market expectations are based on aggressive assumptions: that high-margin (over 70%) digital medical solutions can quickly scale, enabling the company to turn profitable by 2026.

Institutions like Huasheng Securities set a target price of HKD 150, based on forecasts of mid-to-high revenue growth. But this valuation shift still carries uncertainties.

Globally, giants like Teladoc have experienced dramatic market value fluctuations, warning that AI medical stories lacking stable scenario entry points are highly fragile. The current stock price increase is largely a preemptive overreach by capital, betting on policy windfalls and concept hype.

Fundamentally, market trading on Health 160 revolves around three main logics: first, the medical data entry point—accumulated doctor-patient resources as core production factors in the AI era; second, the trillion-yuan consumer medical referral market—high-margin services like dental and cosmetic medicine seen as true profit sources; third, the recent surge in medical AI logic.

Compared to overseas peers like Zocdoc or Hims & Hers, which face scenario limitations, Health 160’s core advantage lies in its deep hospital network. If the “AI hospital” model can be successfully replicated, the platform will upgrade from a simple traffic tool to an industry digital infrastructure.

Of course, the story’s success also depends on three key variables: whether the stickiness of medical traffic entry points is strong enough to avoid user “use-and-leave” issues; whether high-margin consumer medical services can be delivered as planned; and the depth of integration between medical data and AI.

The internet healthcare industry has entered the “precision cultivation” phase. As traffic dividends fade, technological operational capabilities will determine the ceiling.

For investors, Health 160 could grow into a “rentier” in the medical AI era through industry accumulation, or it could revert to the valuation of a “registration platform” under the dual pressures of unlocks and performance doubts.

In this high-stakes game, the market is paying a hefty premium for “possibilities.” Whether this premium translates into real profits will decide if this valuation revolution is a ticket to new horizons or another bubble burst.

When the “crab farming” craze subsides, the market will ultimately reassess the authenticity of its profit model restructuring.